8-K: Evofem Biosciences Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics

Evofem Biosciences anticipates a 55%-60% decrease in PHEXXI manufacturing costs through a new agreement with Windtree Therapeutics.

Summary

• Evofem Biosciences has entered into a License and Supply Agreement with Windtree Therapeutics.
• Windtree will serve as Evofem's sourcing partner for PHEXXI.
• Evofem expects a 55% to 60% reduction in PHEXXI's cost of goods sold (COGS) from current levels.
• There will be no cost to Evofem for the tech transfer to the new manufacturer engaged by Windtree.
• Evofem aims to expand PHEXXI into price-sensitive global markets.
• Windtree has engaged a pharmaceutical manufacturer to produce PHEXXI at a lower cost while maintaining high quality.
• Evofem maintains ownership of the asset and continues to commercialize PHEXXI in the United States and internationally.
• Evofem broadened its commercial offering with the acquisition of SOLOSEC in July 2024.

Sentiment

Score: 8

Explanation: The document presents a positive outlook due to the expected cost reduction and potential for global expansion. The partnership with Windtree is a strategic move that could improve Evofem's financial performance and market position.

Positives

• Significant reduction in PHEXXI manufacturing costs is expected.
• No cost to Evofem for the tech transfer process.
• Potential for global expansion into price-sensitive markets.
• Continued commercialization of PHEXXI in the United States and internationally.
• Maintains ownership of the PHEXXI asset.
• Aditxt is expected to make a $1,500,000 investment on or before April 7, 2025.

Risks

• The expected cost reduction is dependent on Windtree's ability to successfully leverage its manufacturing contacts.
• Global expansion plans are subject to regulatory approvals and market conditions.
• The merger with Aditxt is subject to shareholder approval and other conditions.

Future Outlook

Evofem anticipates expanding PHEXXI into new, price-sensitive global markets and continuing its commercialization efforts in the United States and internationally. The company also expects to complete its merger with Aditxt, Inc.

Management Comments

• Saundra Pelletier, CEO of Evofem, stated that the cost reduction should allow Evofem to take PHEXXI into new, price-sensitive global markets where there is great need for non-hormonal contraceptives that women control.
• Jed Latkin, CEO of Windtree, noted that they have engaged with a pharmaceutical manufacturer on the plan to produce PHEXXI at a far lower cost while delivering the same high quality product.

Industry Context

The agreement with Windtree Therapeutics reflects a broader industry trend of pharmaceutical companies seeking to optimize manufacturing costs and expand into new markets. The focus on non-hormonal contraceptives aligns with growing consumer demand for alternative options in women's health.

Comparison to Industry Standards

• Evofem's partnership with Windtree to reduce manufacturing costs is a common strategy in the pharmaceutical industry, similar to how Teva Pharmaceuticals outsources production to lower-cost manufacturers.
• The target cost reduction of 55%-60% is significant and could make PHEXXI more competitive in price-sensitive markets, potentially mirroring the success of generic drugs in expanding access to medications.
• Evofem's global expansion plans are similar to those of multinational pharmaceutical companies like Bayer, which markets its contraceptive products worldwide.

Stakeholder Impact

• Shareholders may benefit from the expected cost reduction and potential for global expansion.
• Customers may benefit from increased access to PHEXXI in new markets.
• Employees may benefit from the company's growth and expansion.

Next Steps

• Windtree will proceed with the tech transfer to the new manufacturer.
• Evofem will continue commercializing PHEXXI in the United States and internationally.
• Evofem will hold a shareholder meeting to approve the merger with Aditxt.
• Evofem will file a proxy statement with the SEC.

Key Dates

Keywords

PHEXXI, Evofem, Windtree Therapeutics, manufacturing cost, contraceptive, global expansion, SOLOSEC, merger, Aditxt